Abatacept: from a budget impact model to cost-effectiveness analysis – data from RCT and real life

Abatacept: from a budget impact model to cost-effectiveness analysis – data from RCT and real life

Maurizio Benucci,1 Arianna Damiani,1 Mariangela Manfredi,2 Maria Infantino,2 Valentina Grossi,2 Francesca Li Gobbi11Rheumatology Unit, S.Giovanni di Dio Hospital, Florence, Italy; 2Immunology and Allergology Laboratory Unit, S.Giovanni di Dio Hospital, Azienda USL-Toscana Centro, Florence, ItalyAbst...

Full description

Bibliographic Details
Main Authors:	Benucci M, Damiani A, Manfredi M, Infantino M, Grossi V, Li Gobbi F
Format:	Article
Language:	English
Published:	Dove Medical Press 2019-06-01
Series:	ClinicoEconomics and Outcomes Research
Subjects:	Abatacept budget impact model cost-effectiveness analysis rheumatoid arthritis
Online Access:	https://www.dovepress.com/abatacept-from-a-budget-impact-model-to-cost-effectiveness-analysis-da-peer-reviewed-article-CEOR

Similar Items

Factors correlated with the improvement of endothelial dysfunction during Abatacept therapy in patients with rheumatoid arthritis
by: Benucci M, et al.
Published: (2018-06-01)

Actual Persistence of Abatacept in Rheumatoid Arthritis: Results of the French-Ric Network
by: Jean-Hugues Salmon, et al.
Published: (2020-05-01)

Mean cost per number needed to treat with tocilizumab plus methotrexate versus abatacept plus methotrexate in the treatment of rheumatoid arthritis in patients previously treated with methotrexate
by: Benucci M, et al.
Published: (2017-07-01)

Efficacy, safety and tolerability of using abatacept for the treatment of rheumatoid arthritis
by: Rafael Venson, et al.
Published: (2012-12-01)

ABATACEPT IN TREATMENT OF JUVENILE IDIOPATHIC ARTHRITIS: INTERNATIONAL DATA AND EXPERIENCE OF USAGE IN THE REPUBLIC OF MORDOVIA
by: L. A. Balykova, et al.
Published: (2014-03-01)

Cost-utility analysis of abatacept in rheumatoid arthritis in Italy
by: Simona de Portu, et al.
Published: (2008-03-01)

Experience with abatacept used in the treatment of patients with rheumatoid arthritis
by: V I Mazurov, et al.
Published: (2011-12-01)

EXPERIENCE OF TREATMENT WITH ABATACEPT IN PATIENTS WITH JUVENILE RHEUMATOID ARTHRITIS
by: Ye. I. Alekseyeva, et al.
Published: (2011-01-01)

EXPERIENCE OF TREATMENT WITH ABATACEPT IN PATIENTS WITH JUVENILE RHEUMATOID ARTHRITIS
by: Ye. I. Alekseyeva, et al.
Published: (2011-01-01)

Pre-silencing of genes involved in the electron transport chain (ETC) pathway is associated with responsiveness to abatacept in rheumatoid arthritis
by: C. Derambure, et al.
Published: (2017-05-01)

Abatacept and cardiovascular risk in rheumatoid arthritis: update
by: T. V. Popkova
Published: (2018-01-01)

Identification of molecules associated with response to abatacept in patients with rheumatoid arthritis
by: Waka Yokoyama-Kokuryo, et al.
Published: (2020-03-01)

Safety and efficacy of abatacept among patients with refractory rheumatoid arthritis: Experience from a North Indian Tertiary Care Hospital
by: M N Arjun, et al.
Published: (2018-01-01)

Sustained Long-Term Retention Rates of Abatacept in Combination with Conventional Synthetic Disease-Modifying Antirheumatic Drugs in Elderly Patients with Rheumatoid Arthritis
by: Shuzo Sato, et al.
Published: (2021-08-01)

COMPARATIVE EVALUATION OF THE EFFICACY AND SAFETY OF ABATACEPT IN PATIENTS WITH DIFFERENT DURATION OF RHEUMATOID ARTHRITIS
by: M. A. Borisova, et al.
Published: (2017-01-01)

Cost per responder for upadacitinib vs abatacept in patients with moderate-to-severe Rheumatoid Arthritis in Italy
by: Roberto Caporali, et al.
Published: (2021-07-01)

Multicenter, observational clinical study of abatacept in Japanese patients with rheumatoid arthritis
by: Noriyoshi Ogawa, et al.
Published: (2019-01-01)

Safety of Abatacept in Italian Patients with Rheumatoid Arthritis and Interstitial Lung Disease: A Multicenter Retrospective Study
by: Giulia Cassone, et al.
Published: (2020-01-01)

Efficacy and tolerability of abatacept treatment: results of 12 months observation
by: M A Borisova, et al.
Published: (2018-05-01)

Effects of denosumab on bone metabolism and bone mineral density with anti-TNF inhibitors, tocilizumab, or abatacept in osteoporosis with rheumatoid arthritis
by: Suzuki T, et al.
Published: (2018-03-01)

Re-administration of abatacept for the control of articular symptoms of rheumatoid arthritis during anti-tuberculous therapy
by: Hironori Kawamoto, M.D., et al.
Published: (2017-01-01)

Safety of abatacept compared with other biologic and conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: data from an observational study
by: Gulsen Ozen, et al.
Published: (2019-06-01)

EXPERIENCE WITH ABATACEPT IN TREATMENT OF JUVENILE IDIOPATHIC ARTHRITIS
by: Margarita Fedorovna Dubko, et al.
Published: (2012-10-01)

Immunoprofiling for Prediction of Response to Abatacept in Rheumatoid Arthritis Patients
by: Prodromos Sidiropoulos, et al.
Published: (2016-01-01)

Abatacept in rheumatoid arthritis: survival on drug, clinical outcomes, and their predictors—data from a large national quality register
by: Giovanni Cagnotto, et al.
Published: (2020-01-01)

Impact of Single-Nucleotide Polymorphisms of <i>CTLA-4</i>, <i>CD80</i> and <i>CD86</i> on the Effectiveness of Abatacept in Patients with Rheumatoid Arthritis
by: Noelia Marquez Pete, et al.
Published: (2020-11-01)

Outcomes in rheumatoid arthritis patients treated with abatacept: a UK multi-centre observational study
by: Ernest Choy, et al.
Published: (2021-02-01)

Impact of the HLA-DRB1 shared epitope on responses to treatment with tofacitinib or abatacept in patients with rheumatoid arthritis
by: Wataru Hirose, et al.
Published: (2021-08-01)

Comparative risk of malignancies and infections in patients with rheumatoid arthritis initiating abatacept versus other biologics: a multi-database real-world study
by: Teresa A. Simon, et al.
Published: (2019-11-01)

Anti-cyclic citrullinated peptide antibodies – a role in rheumatoid arthritis and the possibility of seroconversion: A focus on abatacept
by: N. V. Chichasova
Published: (2017-03-01)

Redução das imunoglobulinas induzida pelo abatacepte não se associa com eventos infecciosos
by: Valquiria Garcia Dinis
Published: (2017)

Redução das imunoglobulinas induzida pelo abatacepte não se associa com eventos infecciosos
by: Dinis, Valquiria Garcia
Published: (2017)

Abatacept reduces disease activity of rheumatoid arthritis independently of modulating anti-citrullinated peptide antibody production
by: Hisakata Yamada, et al.
Published: (2020-04-01)

Uso do abatacepte em uma paciente com artrite psoriásica Use of the abatacept in a patient with psoriatic arthritis
by: Carlos Ewerton Maia Rodrigues, et al.
Published: (2010-06-01)

EXPERIENCE OF ABATACEPT TREATMENT IN A PATIENT WITH ANTIBODY-POSITIVE IDIOPATHIC JUVENILE ARTHRITIS
by: T. M. Bzarova, et al.
Published: (2012-03-01)

EFFICACY OF ABATACEPT IN A PATIENT WITH POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS REFRACTORY TO TNF-α
by: Yu. M. Spivakovskii, et al.
Published: (2015-04-01)

Interleukin-10-producing LAG3+ regulatory T cells are associated with disease activity and abatacept treatment in rheumatoid arthritis
by: Shinichiro Nakachi, et al.
Published: (2017-05-01)

Budget impact analysis of the use of rituximab in the treatment of rheumatoid arthritis in Italy
by: Maurizio Benucci, et al.
Published: (2009-03-01)

Efficacy of Abatacept Therapy in a Patient with Juvenile Idiopathic Arthritis and Bilateral Uveitis
by: Lelia A. Galstian, et al.
Published: (2016-08-01)

EXPERIENCE OF TREATMENT OF THE TWINS SICK WITH JUVENILE IDIOPATHIC ARTHRITIS BY ABATACEPT
by: V. A. Kel'tsev
Published: (2014-05-01)

Cannot write session to /tmp/vufind_sessions/sess_252s9jt7994765burirbpdoacq